Abstract
Background: Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions. Abraxane, a newer, CremophorYfree form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. Case Reports: Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and 1 cervical malignancy) received Abraxane after having a hypersensitivity reaction to paclitaxel. All five patients tolerated Abraxane well, experiencing no reactions or major side effects to the drug. Discussion: Abraxane is well tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction. Further studies are ongoing to determine the clinical activity of Abraxane in the treatment of these malignancies.
Original language | English (US) |
---|---|
Pages (from-to) | 1281-1283 |
Number of pages | 3 |
Journal | International Journal of Gynecological Cancer |
Volume | 19 |
Issue number | 7 |
DOIs | |
State | Published - Oct 1 2009 |
Externally published | Yes |
Keywords
- Abraxane
- Chemotherapy
- Hypersensitivity reaction
- Paclitaxel
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology